In SMARCA4 mutant lung cancers, STK11 co-mutation is present in 39% and KRAS co-mutation in 36% of cases: its presence with either of these 2 mutations confers a significantly worse prognosis, with an additive effect for co-mutation in all 3 genes37. This evidence concerns the gene KRAS and lung carcinoma.